Table 5.

Estimates of the effect of indoleamine 2,3-dioxygenase 1 (IDO1) protein and kynurenine--oxoglutarate transaminase 3 (KAT3) protein on prostate cancer, lung and bronchus cancer and breast cancer using Mendelian Randomization with different methods.

Outcome	Exposure (SD)	SNPs	Method	OR	95%CI	P value	Cochran’s Q statistic (p-value)	MR-Egger
								Intercept p value	I2
prostate cancer	IDO1	3a	IVW	0.96	0.93, 0.99	0.01	4.43 (0.11)	0.38	93.6%
			MR-Egger	0.89	0.74, 1.06	0.19
			WM	0.96	0.92, 1.00	0.04
		8	IVW	0.96	0.93, 0.99	0.01	8.25 (0.31)	0.44	94.4%
			MR-Egger	0.94	0.87, 1.01	0.08
			WM	0.96	0.92, 1.00	0.03
			MR-PRESSO	0.96	0.93, 0.99	0.01
	KAT3	2b	IVW	0.98	0.92, 1.03	0.42	4.26 (0.04)
		15	IVW	1.00	0.95, 1.04	0.83	28.88 (0.01)	0.85	36.4%
			MR-Egger	0.99	0.90, 1.08	0.79
			WM	1.00	0.95, 1.05	0.95
			MR-PRESSO	1.00	0.95, 1.04	0.84
lung and bronchus cancer	IDO1	3a	IVW	1.04	0.93, 1.17	0.48	0.25 (0.88)	0.81	92.9%
			MR-Egger	0.99	0.66, 1.51	0.98
			WM	1.04	0.92, 1.18	0.52
		8	IVW	1.00	0.90, 1.11	0.94	5.83 (0.56)	0.11	94.5%
			MR-Egger	1.18	0.94, 1.50	0.16
			WM	1.03	0.91, 1.17	0.66
			MR-PRESSO	1.00	0.91, 1.10	0.94
	KAT3	2b	IVW	1.00	0.81, 1.24	0.97	0.31 (0.58)
		15	IVW	1.09	0.96, 1.22	0.18	14.36 (0.42)	0.66	37.3%
			MR-Egger	1.03	0.79, 1.34	0.82
			WM	1.05	0.89, 1.24	0.54
			MR-PRESSO	1.09	0.96, 1.22	0.18
breast cancer	IDO1	3a	IVW	0.99	0.97, 1.02	0.54	1.48 (0.48)	0.26	93.3%
			MR-Egger	0.94	0.87, 1.03	0.21
			WM	0.99	0.96, 1.02	0.52
		8	IVW	0.99	0.97, 1.01	0.37	7.55 (0.37)	0.80	94.3%
			MR-Egger	0.98	0.93, 1.04	0.56
			WM	0.98	0.95, 1.01	0.21
			MR-PRESSO	0.99	0.97, 1.01	0.38
	KAT3	2b	IVW	1.03	0.98, 1.08	0.19	12.62 (<0.01)
		15	IVW	1.00	0.97, 1.04	0.89	26.80 (0.02)	0.54	33.4%
			MR-Egger	0.98	0.91, 1.06	0.63
			WM	0.99	0.95, 1.03	0.51
			MR-PRESSO (corrected)	0.99	0.96, 1.01	0.29

^aNot enough instrumental variables for MR-PRESSO. ^bNot enough instrumental variables for MR-Egger, WM and MR-PRESSO.